Dantrolene
Last Updated: 04/28/2026
Need to find the closest trial?
Sort By Distance
Save trials for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
1 clinical trial found
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Who is this study for: Patients with Multiple Sclerosis
Enrollment Status: Recruiting
Publish Date: April 06, 2026
Intervention Type: Drug
Study Drugs: Pioglitazone, Clemastine Fumarate, Hydroxychloroquine, Dantrolene
Study Phase: Phase 1/Phase 2
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to.
Showing 1-1 of 1
Last Updated: 04/28/2026